Dark Pharma · DP-028
HE REJECTED THE PATENT IN ROOM 402. GLOBAL COUNSEL FILED SEVENTEEN APPEALS. HE KEPT THE CARBON COPY.
On August 4, 2006, Anand Kapoor rejected Helix Pharma’s patent application for imesitran mesylate, based on Section 3d of the Patents Act. Despite having clear legal grounds, Helix filed seventeen appeals, leading to seven years of litigation that ultimately culminated in a Supreme Court decision against them.
Case Assets
The Case Debrief is free to view. Full Case Study, Teaching Notes, Slide Deck, Discussion Guide, and Assessment are available with a Premium subscription.
Brief the Board
PREMIUM
🔒 Unlock
Learn the Case
FREE — included
Study the Case
PREMIUM
🔒 Unlock
Teach the Case
PREMIUM
🔒 Unlock
Present the Case
PREMIUM
🔒 Unlock
Run a Team Discussion
PREMIUM
🔒 Unlock
Test Your Judgement
PREMIUM
🔒 Unlock
Watch the Full Episode
The complete cinematic audio documentary — Dark Pharma
Unlock the Full Case Library
Get every Case Study, Slide Deck, Teaching Notes, Discussion Guide, and Assessment — across a growing library of business cases.
View Pricing →Related Cases
Cases that share a governance or behavioural model with this one.
Dark Law
DL-027
HE WORE THE WIRE TO FORTY-FIVE MEETINGS. THE FBI CALLED HIM THEIR BEST...
Shared: Risk Assessment Framework
Sovereign Games
SG-038
HE SIGNED FOR EIGHTEEN MILLION. THE MINISTRY KEPT IT SECRET FOR FOURTE...
Shared: Risk Assessment Framework
Sovereign Games
SG-037
HE PROCESSED ELEVEN MILLION IN FOUR YEARS. THE LEDGER SAID SEISMIC TES...
Shared: Risk Assessment Framework
Machine Room
MX-037
SHE SET THE THRESHOLD AT EIGHTY-SEVEN PERCENT. FLEETRIDE TERMINATED SI...
Shared: Risk Assessment Framework